alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ludvik Rolin, President and Chief Executive Officer of Victory Eagle Resources Corp., certify that:

1.	I have reviewed this annual report on Form 10-KSB of Victory Eagle Resources Corp.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4.	The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)	Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c)	Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and

5.	The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date:  November 15, 2006

/s/ Ludvik Rolin	Ludvik Rolin
President and Chief Executive Officer
(Principal Executive Officer)
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
     (This schedule  contains summary financial  information  extracted from (A)
Consolidated  Balance Sheets,  Statements of Operations,  Change in Stockholders
Equity and Cash Flows and is  qualified in its entirety by reference to such (B)
quarterly report on Form 10-Q for the three months ended March 31, 1998)
</LEGEND>
       
<S>                                     <C>
<PERIOD-TYPE>                           3-MOS
<FISCAL-YEAR-END>                       DEC-31-1998
<PERIOD-END>                            MAR-30-1998
<CASH>                                       30,339
<SECURITIES>                                      0
<RECEIVABLES>                                     0
<ALLOWANCES>                                      0
<INVENTORY>                                       0
<CURRENT-ASSETS>                             32,298
<PP&E>                                        8,608
<DEPRECIATION>                                  993
<TOTAL-ASSETS>                               91,338
<CURRENT-LIABILITIES>                     1,044,437
<BONDS>                                           0
<PREFERRED-MANDATORY>                             0
<PREFERRED>                                       0
<COMMON>                                    144,324
<OTHER-SE>                               (1,097,423)
<TOTAL-LIABILITY-AND-EQUITY>                 91,338
<SALES>                                           0
<TOTAL-REVENUES>                                  0
<CGS>                                             0
<TOTAL-COSTS>                                     0
<OTHER-EXPENSES>                            163,339
<LOSS-PROVISION>                                  0
<INTEREST-EXPENSE>                            6,831
<INCOME-PRETAX>                            (170,170)
<INCOME-TAX>                                      0
<INCOME-CONTINUING>                        (170,170)
<DISCONTINUED>                                    0
<EXTRAORDINARY>                                   0
<CHANGES>                                         0
<NET-INCOME>                               (170,170)
<EPS-PRIMARY>                                     0
<EPS-DILUTED>                                     0
        

</TABLE>
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2610 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2610

 To extend the temporary suspension of duty on Esfenvalerate technical.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 7, 2012

   Mr. Coons introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To extend the temporary suspension of duty on Esfenvalerate technical.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ESFENVALERATE TECHNICAL.

    (a) In General.--Heading 9902.01.45 of the Harmonized Tariff 
Schedule of the United States (relating to (S)-cyano(3-
phenoxyphenyl)methyl (S)-4-chloro-a-(1-methylethylbenzeneacetate 
(Esfenvalerate)) is amended by striking the date in the effective 
period column and inserting ``12/31/2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
Exhibit 10.78

 

Addendum to Change Order Form # 8

 

Change order under Agreement dated:  the Development and Clinical Supplies Agreement dated June 19, 2009, as amended by the Amendment dated as of December 31, 2009, the Second Amendment dated as of September 16, 2010, the Third Amendment dated as of September 29, 2010 and the Fourth Amendment dated March 2, 2011 (the “Agreement”).

 

Between:  Radius Health, Inc and 3M

 

Project Name:  For the development of Radius’s BA-058 compound delivered via 3M’s Microstructured Transdermal Delivery System

 

Change requested by:  Radius

Name:  Maria Grunwald and Gary Hattersley

Company:  3M

Date:  20 July 2011, Addendum 12 August 2011

Description of change:

 

As per Change Order #8, Radius has requested 3M manufacture 420 patches for an additional clinical study Radius wishes to conduct. An additional 12 patches are required per the addendum for visual inspection at time of release.  The product strength is [*]mcg/array.

 

	
Planned Usage
    	
 
    	
Number of Patches
    
	
Clinical   study supplies
    	
 
    	
[*]
    
	
Release   testing
    	
 
    	
[*]   + 12 (visual inspection)
    
	
Retains
    	
 
    	
[*]
    
	
Stability
    	
 
    	
[*]
    
	
Customer   retains
    	
 
    	
0
    
	
Total   Quantity
    	
 
    	
420 +   12 = 432
    


 

The addendum to change order 8 is estimated to add 58 additional hours including, but not limited to visual examination of returned arrays and residual drug content analysis on [*] arrays.

 

Except to the extent expressly amended by this Change Order, the terms and conditions of the Agreement remain in full force and effect.  The term “Agreement”, as used in the Agreement, shall henceforth be deemed to be a reference to the Agreement as amended by this Change Order.

 




* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

1











 

Requested task, dates and costs are approved by:

 


	
Company:   Radius Health, Inc
    	
 
    	
Company:   3M
    
	
Name:   Nick Harvey
    	
 
    	
Name:   Mary Mathisen
    
	
Signature:
    	
/s/Nick   Harvey
    	
 
    	
Signature:
    	
/   Mary Mathisen
    
	
Position:   CFO
    	
 
    	
Position:   Commercialization Mgr
    
	
Date   (dd/mm/yy): August 12, 2011
    	
 
    	
Date   (dd/mm/yy): 16 August 2011
    
					




 

2
Form 52-109F1 Certification of Annual Filings



I, Michael W. Kinley, Chief Financial Officer, certify that:



1.

I have reviewed the annual filings (as this term is defined in Multilateral Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings) of Cardero Resource Corp. (the issuer) for the period ending October 31, 2005 and 2004;



2.

Based on my knowledge, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the annual filings;



3.

Based on my knowledge, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, results of operations and cash flows of the issuer, as of the date and for the periods presented in the annual filings;



4.

The issuers other certifying officers and I, are responsible for establishing and maintaining disclosure controls and procedures and internal control over financial reporting for the issuer, and we have:



(a)

designed such disclosure controls and procedures, or caused them to be designed under our supervision, to provide reasonable assurance that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the annual filings are being prepared;



(b)

designed such internal control over financial reporting, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers GAAP; and



(c)

evaluated the effectiveness of the issuers disclosure controls and procedures as of the end of the period covered by the annual filings and have caused the issuer to disclose in the annual MD&A our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by the annual filings based on such evaluation; and



5.

I have caused the issuer to disclose in the annual MD&A any change in the issuers internal control over financial reporting that occurred during the issuers most recent interim period that has materially affected, or is reasonably likely to materially affect, the issuers internal control over financial reporting.



Date:

January 26, 2006





Michael W. Kinley (signed)



Michael W. Kinley,

Chief Financial Officer
<TABLE> <S> <C>

<ARTICLE>                     5

<S>                                      <C>
<PERIOD-TYPE>                            3-MOS
<FISCAL-YEAR-END>              MAR-31-2001
<PERIOD-START>                 APR-01-2000
<PERIOD-END>                   JUN-30-2000
<CASH>                                  0
<SECURITIES>                            0
<RECEIVABLES>                           0
<ALLOWANCES>                            0
<INVENTORY>                             0
<CURRENT-ASSETS>                        0
<PP&E>                                  0
<DEPRECIATION>                          0
<TOTAL-ASSETS>                          0
<CURRENT-LIABILITIES>                   0
<BONDS>                                 0
<PREFERRED-MANDATORY>                   0
<PREFERRED>                             0
<COMMON>                                0
<OTHER-SE>                              0
<TOTAL-LIABILITY-AND-EQUITY>            0
<SALES>                         2,083,504
<TOTAL-REVENUES>                2,083,504
<CGS>                           1,157,102
<TOTAL-COSTS>                   5,647,311
<OTHER-EXPENSES>                        0
<LOSS-PROVISION>                        0
<INTEREST-EXPENSE>                (20,873)
<INCOME-PRETAX>                (4,611,667)
<INCOME-TAX>                       23,572
<INCOME-CONTINUING>            (4,635,239)
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0
<CHANGES>                               0
<NET-INCOME>                   (4,635,239)
<EPS-BASIC>                         (0.31)
<EPS-DILUTED>                       (0.31)


</TABLE>
II 

112TH CONGRESS 

2D SESSION S. 2895 

To suspend temporarily the duty on 1,3,5-triazine, 2,4,6-tris(2-propenyloxyl)- 

. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. MENENDEZ introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To suspend temporarily the duty on 1,3,5-triazine, 2,4,6- 

tris(2-propenyloxyl)-. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 1,3,5-TRIAZINE, 2,4,6-TRIS(2-PROPENYLOXYL)-. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 

‘‘ 9902.01.00 1,3,5-Triazine, 2,4,6-tris(2- 

propenyloxyl)- (CAS No. 

101–37–1) (provided for in 

subheading 2933.69.60) ........ Free No change No change On or before 

12/31/2015 ’’. 


jbell on DSK7SPTVN1PROD with BILLS
2 

•S 2895 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
STATE EX REL. Andrew D. CRITTON v. STATE of Louisiana

No. 2018-KH-0339

Supreme Court of Louisiana.

April 16, 2018

**ON SUPERVISORY WRITS TO THE SECOND JUDICIAL DISTRICT COURT, PARISH OF BIENVILLE**

PER CURIAM:

WRIT NOT CONSIDERED. Petitioner has not demonstrated that he sought review in the court(s) below before filing in this Court nor shown the "extraordinary circumstances" that would justify bypassing that level of review. La.S.Ct.R. X § 5(b).
II 

112TH CONGRESS 

2D SESSION S. 3033 

To extend the temporary suspension of duty on ethene, tetrafluoro, oxidized, 

polymerized reduced, methyl esters, reduced. 

IN THE SENATE OF THE UNITED STATES 

MAY 9, 2012 

Mr. LAUTENBERG introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on ethene, 

tetrafluoro, oxidized, polymerized reduced, methyl esters, 

reduced. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ETHENE, TETRAFLUORO, OXIDIZED, POLYM4 ERIZED REDUCED, METHYL ESTERS, RE5 DUCED. 

6 (a) IN GENERAL.—Heading 9902.23.19 of the Har7 monized Tariff Schedule of the United States (relating to 

8 ethene, tetrafluoro, oxidized, polymerized reduced, methyl 

9 esters, reduced) is amended by striking the date in the 

10 effective period column and inserting ‘‘12/31/2015’’. 


jbell on DSK7SPTVN1PROD with BILLS
2 

•S 3033 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of the Interior

###### Bureau of Land Management 

          - [LLWY-957400-09-L14200000-BJ0000-TRST] 

# AGENCY:

Bureau of Land Management, Interior. 

# ACTION:

Notice of Filing of Plats of Survey, Nebraska.

# SUMMARY:

The Bureau of Land Management (BLM) is scheduled to file the plat of survey of the lands described below thirty (30) calendar days from the date of this publication in the BLM Wyoming State Office, Cheyenne, Wyoming. 

# FOR FURTHER INFORMATION CONTACT:

Bureau of Land Management, 5353 Yellowstone Road, P.O. Box 1828, Cheyenne, Wyoming 82003. 

# SUPPLEMENTARY INFORMATION:

This survey was executed at the request of the Bureau of Indian Affairs and is necessary for the management of these lands. The lands surveyed are: 

The plat and field notes representing the dependent resurvey of portions of the First Guide Meridian East, through T. 24 N., between Rs. 8 and 9 E., the east boundary, subdivisional lines and subdivision of certain sections, and the corrective dependent resurvey of a portion of the subdivisional lines and subdivision of section 22, and the survey of the subdivision of certain sections, Township 24 North, Range 9 East, of the Sixth Principal Meridian, Nebraska, was accepted April 13, 2009. 

Copies of the preceding described plat are available to the public at a cost of $1.10 per page. 

Dated: April 14, 2009. 

John P. Lee, 

Chief Cadastral Surveyor, Division of Support Services.

[FR Doc. E9-9003 Filed 4-17-09; 8:45 am] 

BILLING CODE 4467-22-P
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AND STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 1997.   

</LEGEND>

       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-START>                             JUL-01-1996
<PERIOD-END>                               MAR-31-1997
<CASH>                                       2,010,818
<SECURITIES>                                         0
<RECEIVABLES>                                3,769,812
<ALLOWANCES>                                    60,000
<INVENTORY>                                  9,852,482
<CURRENT-ASSETS>                            20,993,911
<PP&E>                                      70,931,294
<DEPRECIATION>                            (14,022,731)
<TOTAL-ASSETS>                              77,902,474
<CURRENT-LIABILITIES>                       11,843,055
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        707
<COMMON>                                       974,671
<OTHER-SE>                                  16,409,041
<TOTAL-LIABILITY-AND-EQUITY>                77,902,474
<SALES>                                      3,725,463
<TOTAL-REVENUES>                             3,980,791
<CGS>                                       10,827,680
<TOTAL-COSTS>                                2,526,782
<OTHER-EXPENSES>                               622,530
<LOSS-PROVISION>                                60,000
<INTEREST-EXPENSE>                             932,582
<INCOME-PRETAX>                            (9,996,201)
<INCOME-TAX>                               (3,501,690)
<INCOME-CONTINUING>                        (6,494,511)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (6,494,511)
<EPS-PRIMARY>                                    (.08)
<EPS-DILUTED>                                    (.08)
        

</TABLE>
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>


<ARTICLE>                     5
       
<S>                             <C>
<PERIOD-TYPE>                   3-M0S
<FISCAL-YEAR-END>                              DEC-31-1996
<PERIOD-START>                                 JAN-01-1997
<PERIOD-END>                                   MAR-31-1997 
<CASH>                                         184,623
<SECURITIES>                                   0
<RECEIVABLES>                                  407,901
<ALLOWANCES>                                   (56,591)
<INVENTORY>                                    0
<CURRENT-ASSETS>                               0
<PP&E>                                         5,726,239
<DEPRECIATION>                                 (1,993,173)
<TOTAL-ASSETS>                                 5,088,062
<CURRENT-LIABILITIES>                          0
<BONDS>                                        4,508,583
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     378,211
<TOTAL-LIABILITY-AND-EQUITY>                   5,088,062
<SALES>                                        892,250
<TOTAL-REVENUES>                               1,165,141
<CGS>                                          0
<TOTAL-COSTS>                                  812,881
<OTHER-EXPENSES>                               148,342
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             124,233
<INCOME-PRETAX>                                79,685
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            79,685
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   79,685
<EPS-PRIMARY>                                  9.84
<EPS-DILUTED>                                  9.84
<FN>
                    NOTE:  TOTAL CURRENT ASSETS AND TOTAL CURRENT LIABILITIES
                           ARE NOT APPLICABLE BECAUSE REGISTRANT DOES NOT
                           PRESENT A CLASSIFIED BALANCE SHEET.
</FN>
        


</TABLE>